TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16814412

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15591730

Group type: EXPERIMENTAL
Intervention: Information on tooth-brushing techniques
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Prescription of fluoride lozenges
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Semi-annual applications of fluoride varnish
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Quarterly appointments with individualized information and fluoride varnish application
Number of subjects: 925

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 925
Study: 12405170

Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 2 mg/kg/day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 2 mg/kg/every other day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 1 mg/kg/day
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 10519502

Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 30
Study: 7745517

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 344

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 344
Study: 1981317

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 12
Study: 6994301

Group type: EXPERIMENTAL
Intervention: Single-morning daily prednisone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternate-day prednisone treatment
Number of subjects: 0
Study: 31174055

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 28490674

Group type: EXPERIMENTAL
Intervention: Liquid oil (22.25 g coconut oil or sunflower oil)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oleogel (25 g coconut oleogel or sunflower oleogel)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (orange juice and rice porridge)
Number of subjects: 16
Study: 25844709

Group type: EXPERIMENTAL
Intervention: Thickened amino acid-based formula (TAAF, Novalac)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reference amino acid-based formula (RAAF, Neocate)
Number of subjects: 75
Study: 23604006

Group type: EXPERIMENTAL
Intervention: Object alternation (OA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Delayed response (DR)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Delayed alternation (DA)
Number of subjects: 3
Study: 22432725

Group type: EXPERIMENTAL
Intervention: Flax seed powder (10 g daily for 1 month)
Number of subjects: 29
Study: 18778967

Group type: EXPERIMENTAL
Intervention: Text messaging reminders
Number of subjects: 102

Group type: COMPARATOR
Intervention: No text messaging activity (Control)
Number of subjects: 102
Study: 17588299

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg once daily
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: indomethacin 50 mg three times daily
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: etoricoxib or indomethacin
Number of subjects: 339
Study: 15450438

Group type: EXPERIMENTAL
Intervention: Simultaneous Communication (SC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Speech Alone (SA)
Number of subjects: 4
Study: 11451727

Group type: EXPERIMENTAL
Intervention: Bread with 1.2 mg Zn and 17 microg folic acid (A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bread with 1.2 mg Zn and 144 microg folic acid (B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bread with 3.0 mg Zn and 17 microg folic acid (C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bread with 2.9 mg Zn and 144 microg folic acid (D)
Number of subjects: 15
Study: 9727794

Group type: EXPERIMENTAL
Intervention: Nocturnal O2 plus CO2
Number of subjects: 9

Group type: COMPARATOR
Intervention: Air applied by nasal prongs (control)
Number of subjects: 9
Study: 7752830

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus CoQ10 100 mg
Number of subjects: 34
Study: 3159346

Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG) combined with MF regimen (MMC + 5‐FU)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG) combined with F regimen (Tegafur)
Number of subjects: 367
Study: 29477372

Group type: EXPERIMENTAL
Intervention: MAPSS‐MS intervention (8-week duration)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual care plus freely available computer games
Number of subjects: 183
Study: 26415090

Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 242
Study: 25041459

Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 427
Study: 22574377

Group type: EXPERIMENTAL
Intervention: Yimusake 1 tablet (50 mg) per day for 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride 1 tablet (50 mg) per day for 4 weeks
Number of subjects: 68
Study: 20377924

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 70
Study: 17825113

Group type: EXPERIMENTAL
Intervention: Individual counselling on diet and physical activity during five routine visits to a public health nurse
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 92
Study: 17686104

Group type: EXPERIMENTAL
Intervention: IL-10 expression in nasal epithelium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroid treatment or allergen provocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline IL-10 expression
Number of subjects: 0
Study: 15844727

Group type: EXPERIMENTAL
Intervention: Skills-based bibliotherapy approach (self-help book)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 110
Study: 10868327

Group type: EXPERIMENTAL
Intervention: Unilateral threshold ECT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Unilateral suprathreshold ECT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bilateral threshold ECT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bilateral suprathreshold ECT
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline RPP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ictal RPP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Postictal RPP
Number of subjects: 28
Study: 9013366

Group type: EXPERIMENTAL
Intervention: rHu GM‐CSF (5 micrograms/kg subcutaneously daily for 4 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rHu GM‐CSF after the first dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg orally every 8 hours)
Number of subjects: 8
Study: 10183639

Group type: EXPERIMENTAL
Intervention: AIDS of unspecified origin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AIDS in a hemophiliac infected by blood transfusion
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Leukemia
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both categories of AIDS patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: All three diagnostic categories
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antigay bias
Number of subjects: 180
Study: 2859713

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 18
Study: 30870744

Group type: EXPERIMENTAL
Intervention: Humorous parody images of thin-ideal celebrity posts
Number of subjects: 102

Group type: COMPARATOR
Intervention: Thin-ideal celebrity images
Number of subjects: 102
Study: 28235506

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with normal dilution (ND group, 35 patients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with 5% dextrose dilution (D5 group, 35 patients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with normal dilution (ND group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with 5% dextrose dilution (D5 group)
Number of subjects: 70
Study: 26238672

Group type: EXPERIMENTAL
Intervention: CZP 200 mg
Number of subjects: 1598

Group type: EXPERIMENTAL
Intervention: CZP 400 mg
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study: 24420340

Group type: EXPERIMENTAL
Intervention: Late-onset Pompe disease patients
Number of subjects: 10
Study: 23923597

Group type: EXPERIMENTAL
Intervention: Nursing intervention (10 sessions: 3 individual, 5 with family, 2 small group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine drug treatment (control group)
Number of subjects: 60
Study: 19389561

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 3565
Study: 17464552

Group type: EXPERIMENTAL
Intervention: Hydration supplementation (1500 ml of water + 1500 mg of NaCl/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 86
Study: 15547181

Group type: EXPERIMENTAL
Intervention: docetaxel-carboplatin
Number of subjects: 1077

Group type: COMPARATOR
Intervention: paclitaxel-carboplatin
Number of subjects: 1077
Study: 11673814

Group type: EXPERIMENTAL
Intervention: HGC‐SQV‐based HAART (Arm A)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: IDV‐based HAART (Arm B)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Both arms (Arm A and Arm B)
Number of subjects: 262
Study: 9271010

Group type: EXPERIMENTAL
Intervention: Aneuploid mAgNOR counts of >= 2.4 in cases associated with malignancy (80% of 16 cases)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Aneuploid mAgNOR counts of >= 2.4 in cases not associated with malignancy (11% of 53 cases)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: pAgNOR counts
Number of subjects: 69
Study: 7909999

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (eye drops and nasal spray)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral terfenadine
Number of subjects: 27
Study: 3299678

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg intravenously twice daily) + Neostigmine (0.5 mg subcutaneously twice daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.5 mg subcutaneously twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 29419920

Group type: EXPERIMENTAL
Intervention: V0034CR emollient
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Reference emollient
Number of subjects: 335

Group type: COMPARATOR
Intervention: No emollient
Number of subjects: 335
Study: 27412490

Group type: EXPERIMENTAL
Intervention: Colored indicator gloves
Number of subjects: 574

Group type: COMPARATOR
Intervention: Standard gloves
Number of subjects: 574
Study: 24738073

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sedentary Control
Number of subjects: 81
Study: 23778903

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study: 20843456

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises (16 sessions, twice a week for 30 minutes)
Number of subjects: 50
Study: 18164521

Group type: EXPERIMENTAL
Intervention: Preventive AIDS vaccine
Number of subjects: 50000000
Study: 16507186

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (systolic blood pressure > 90 mmHg)
Number of subjects: 16
Study: 12222975

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) to guide electrical cardioversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management (cardioversion following 3 weeks of anticoagulation)
Number of subjects: 0
Study: 10590282

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 499

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 1 g iv three-times daily
Number of subjects: 499
Study: 7797060

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled beta 2-agonists
Number of subjects: 0
Study: 2194992

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitrypylinoxide (150 mg/day)
Number of subjects: 0
Study: 115367

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29572676

Group type: EXPERIMENTAL
Intervention: 20 µg/day of vitamin D3
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 10 µg/day of vitamin D3
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 27891629

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcium hydroxide (CH)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both MTA and CH
Number of subjects: 70
Study: 25820474

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.3 g/day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: α-lipoic acid 0.3 g/day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both EPA (1.3 g/day) and α-lipoic acid (0.3 g/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 73
Study: 24059443

Group type: EXPERIMENTAL
Intervention: Interactive Metronome (IM) therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Rehabilitation Care (SRC)
Number of subjects: 46
Study: 21126869

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 464

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: QUAL-EC
Number of subjects: 464
Study: 19576804

Group type: EXPERIMENTAL
Intervention: Brushing with NaviTip FX
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent passive ultrasonic irrigation (PUI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No activation (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous PUI with irrigant delivered at pulp chamber
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous PUI with irrigant delivered through the ultrasonic unit
Number of subjects: 40
Study: 16832589

Group type: EXPERIMENTAL
Intervention: Rehabilitation (REH) - pelvic floor muscle training and behavioral training over 5 visits in 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Medication (MED) - extended release oxybutynin at 5 mg/day for 3 months
Number of subjects: 44
Study: 15516392

Group type: EXPERIMENTAL
Intervention: Oxytocin bolus dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 40
Study: 11353937

Group type: EXPERIMENTAL
Intervention: Mechanical force, manually assisted (MFMA) manipulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Specific contact high-velocity, low-amplitude (HVLA) manipulation
Number of subjects: 30
Study: 9024436

Group type: EXPERIMENTAL
Intervention: Debridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 0
Study: 7934681

Group type: EXPERIMENTAL
Intervention: Head down position without PEEP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Head down position with PEEP 5 cmH2O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lithotomy position without PEEP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lithotomy position with PEEP 5 cmH2O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supine position without PEEP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supine position with PEEP 5 cmH2O
Number of subjects: 60
Study: 3510764

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31551154

Group type: EXPERIMENTAL
Intervention: Cytokine enrichment of culture medium (granulocyte‐macrophage colony‐stimulating factor, heparin‐binding epidermal growth factor‐like growth factor, and leukemia inhibitory factor)
Number of subjects: 443

Group type: COMPARATOR
Intervention: No cytokines (control)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Cytokine enrichment of culture medium
Number of subjects: 443
Study: 28669793

Group type: EXPERIMENTAL
Intervention: 5% methylene blue mediated photodynamic therapy using Fotosan device for 30s (630nm wavelength and 7.2‐14.4J/cm2 dose) for 4 sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5mg tab dexamethasone solution in 5cc water, rinsed 4 times a day for two weeks
Number of subjects: 30
Study: 26134837

Group type: EXPERIMENTAL
Intervention: Culturally tailored, practice-based intervention delivered by bilingual medical assistants trained as Health Coaches
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (standard hypertension treatment recommendations)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Culturally tailored, practice-based intervention
Number of subjects: 148
Study: 23786760

Group type: EXPERIMENTAL
Intervention: Etanercept 2 × 25 mg s.c./week
Number of subjects: 26
Study: 21321333

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study: 20415156

Group type: EXPERIMENTAL
Intervention: Thickest rubber glove (3.1 mm)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Thickest interdigital spacers
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Increasing glove thickness during submaximal object-lifting task
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All gloves (increased thickness)
Number of subjects: 7
Study: 16835670

Group type: EXPERIMENTAL
Intervention: Nurse-centred surveillance and treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (primary care physician follow-up)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Combined endpoint (LDL-C < 2.5 mmol/L, triglycerides < 2.0 mmol/L, total cholesterol/HDL < 4.0)
Number of subjects: 127
Study: 15074086

Group type: EXPERIMENTAL
Intervention: Naoreqing oral liquid (NRQ)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Naoreqing oral liquid (NRQ) plus western medicine (WM)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Western medicine (WM) alone
Number of subjects: 451
Study: 10732177

Group type: EXPERIMENTAL
Intervention: Early tactile stimulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Routine conventional therapy
Number of subjects: 49
Study: 8882986

Group type: EXPERIMENTAL
Intervention: CT plus IFN alpha‐2a (3 MU/m2 twice weekly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 90
Study: 1356319

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (thiopental, nitrous oxide, oxygen, and fentanyl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 2408735

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with methotrexate, bleomycin, and cisplatin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 163
Study: 3324523

Group type: EXPERIMENTAL
Intervention: 3 g single dose of amoxicillin
Number of subjects: 91

Group type: COMPARATOR
Intervention: 4-day course of 3 doses of 750 mg amoxicillin
Number of subjects: 91
Study: 29564846

Group type: EXPERIMENTAL
Intervention: CON/CON (concentric quadriceps and concentric hamstrings, n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ECC/ECC (eccentric quadriceps and eccentric hamstrings, n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CON/ECC (concentric quadriceps and eccentric hamstrings, n=10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CTRL (no training, n=10)
Number of subjects: 40
Study: 28842126

Group type: EXPERIMENTAL
Intervention: Immediate postpartum levonorgestrel intrauterine device insertion
Number of subjects: 259

Group type: COMPARATOR
Intervention: Delayed postpartum levonorgestrel intrauterine device insertion
Number of subjects: 259
Study: 26152218

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: IV saline (Control group)
Number of subjects: 150
Study: 23782128

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (MPH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21587283

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (INT) with individual advice on healthy diet and physical activity for 4.1 years.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (CON) with no specific intervention.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (INT)
Number of subjects: 147
Study: 18423697

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 5alpha-reductase inhibitors (dutasteride and finasteride)
Number of subjects: 99
Study: 16929628

Group type: EXPERIMENTAL
Intervention: Eagle's syndrome group (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control group (n=10)
Number of subjects: 20
Study: 14679474

Group type: EXPERIMENTAL
Intervention: Rifampin and pyrazinamide
Number of subjects: 0
Study: 10711705

Group type: EXPERIMENTAL
Intervention: BQ‐123 (60 microg/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BQ‐123 (120 microg/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9199074

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 x 40 mg per day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Na-heparin 3 x 5000 IE (increased to 3 x 7500 IE if PTT did not reach 40 seconds)
Number of subjects: 226
Study: 1376845

Group type: EXPERIMENTAL
Intervention: Isradipine (0.4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine (2.0 mg)
Number of subjects: 12
Study: 3888386

Group type: EXPERIMENTAL
Intervention: CFP (cyclophosphamide, 5-FU, and prednisone)
Number of subjects: 125

Group type: COMPARATOR
Intervention: CFP plus tamoxifen
Number of subjects: 125